Using AI to improve prostate cancer diagnosis and prognosis

The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis

This study is testing whether advanced AI can help doctors better diagnose and predict outcomes for men with prostate cancer and other prostate conditions.

Quick facts

• Study type: Observational
• Enrollment: 1000 (estimated)
• Ages: 18 Years to 80 Years
• Sex: Male
• Sponsor: Shanghai Changzheng Hospital (Academic / other)
• Locations: 1 site (Shanghai, Shanghai)
• Trial ID: NCT06589154 on ClinicalTrials.gov

What this trial studies

This study explores the use of multimodal artificial intelligence systems to enhance the accuracy of prostate cancer diagnosis and prognosis. By integrating various data types, including imaging, genomics, pathology, and clinical information, the research aims to facilitate precision medicine approaches for prostate cancer. The study leverages advanced AI techniques, such as deep learning and machine learning, to analyze extensive medical datasets, ultimately aiming to improve treatment outcomes and survival rates for patients. Participants will include men with normal prostate conditions, benign prostatic hyperplasia, or prostate cancer who have undergone relevant imaging examinations.

Who should consider this trial

Good fit: Ideal candidates include males aged 18-80 with normal prostate, benign prostatic hyperplasia, or prostate cancer who have had a prostate or pelvic MRI.

Not a fit: Patients with other malignancies diagnosed within the past 5 years or those unsuitable for participation as determined by the investigator may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly enhance diagnostic accuracy and treatment outcomes for prostate cancer patients.

How similar studies have performed: Other studies utilizing multimodal data fusion and AI in cancer diagnostics have shown promising results, indicating potential success for this approach.

Eligibility criteria

Inclusion Criteria:

1. Male, 18-80 years of age;
2. Patients with normal prostate, prostatic hyperplasia, or prostate cancer who have undergone a prostate or pelvic magnetic resonance (MR) examination;
3. First visit on January 1, 2014 or later.

Exclusion Criteria:

1. Patients with a diagnosis of any other malignancy within the previous 5 years;
2. Patients who have undergone transurethral resection or enucleation of the prostate prior to undergoing imaging;
3. Patients who are not suitable for participation in this clinical trial in the judgment of the investigator;

Patients who meet any of the above criteria may not be enrolled as subjects.

Where this trial is running

Shanghai, Shanghai

• Shanghai Changzheng Hospital — Shanghai, Shanghai, China (Recruiting)

Study contacts

• Study coordinator: Shancheng Ren, MD,PhD

Conditions Healthy People; Benign Prostatic Hyperplasia; Prostate Cancer